Pharmaceutics,
Год журнала:
2023,
Номер
15(9), С. 2276 - 2276
Опубликована: Сен. 4, 2023
Inflammatory
diseases
are
common
pathological
processes
caused
by
various
acute
and
chronic
factors,
some
of
them
autoimmune
diseases.
Exosomes
fundamental
extracellular
vesicles
secreted
almost
all
cells,
which
contain
a
series
constituents,
i.e.,
cytoskeletal
cytosolic
proteins
(actin,
tubulin,
histones),
nucleic
acids
(mRNA,
miRNA,
DNA),
lipids
(diacylglycerophosphates,
cholesterol,
sphingomyelin,
ceramide),
other
bioactive
components
(cytokines,
signal
transduction
proteins,
enzymes,
antigen
presentation
membrane
transport/fusion
molecules,
adhesion
molecules).
This
review
will
be
synopsis
the
knowledge
on
contribution
exosomes
from
different
cell
sources
as
possible
therapeutic
agents
against
inflammation,
focusing
several
inflammatory
diseases,
neurological
rheumatoid
arthritis
osteoarthritis,
intestinal
bowel
disease,
asthma,
liver
kidney
injuries.
Current
indicates
that
role
in
therapy
inflammation
could
distinctive.
The
main
limitations
to
their
clinical
translation
still
production,
isolation,
storage.
Additionally,
there
is
an
urgent
need
personalize
treatments
terms
selection
exosomes;
dosages
routes
administration;
deeper
about
biodistribution,
type
incidence
adverse
events,
long-term
effects
exosomes.
In
conclusion,
can
very
promising
next-generation
option,
superior
synthetic
nanocarriers
therapy,
represent
new
strategy
effective,
safe,
versatile,
selective
delivery
systems
future.
Frontiers in Cell and Developmental Biology,
Год журнала:
2023,
Номер
11
Опубликована: Июнь 27, 2023
Accumulating
evidence
indicates
that
most
primary
Wharton’s
jelly
mesenchymal
stem
cells
(WJ-MSCs)
therapeutic
potential
is
due
to
their
paracrine
activity,
i.e.,
ability
modulate
microenvironment
by
releasing
bioactive
molecules
and
factors
collectively
known
as
secretome.
These
can
either
be
released
directly
into
the
surrounding
or
embedded
within
membrane-bound
extracellular
nano-sized
(usually
30–150
nm)
messenger
particles
vesicles
of
endosomal
origin
with
specific
route
biogenesis,
exosomes
carried
relatively
larger
(100
nm–1
μm)
formed
outward
blebbing
plasma
membrane
called
microvesicles
(MVs);
MVs
are
(EVs).
The
found
in
secretome
various
types,
including
cytokines,
chemokines,
cytoskeletal
proteins,
integrins,
growth
factors,
angiogenic
mediators,
hormones,
metabolites,
regulatory
nucleic
acid
molecules.
As
expected,
performs
different
biological
functions,
such
immunomodulation,
tissue
replenishment,
cellular
homeostasis,
besides
possessing
anti-inflammatory
anti-fibrotic
effects.
This
review
highlights
current
advances
research
on
WJ-MSCs’
its
prospective
clinical
applications.
Biology,
Год журнала:
2023,
Номер
12(5), С. 653 - 653
Опубликована: Апрель 26, 2023
Spinal
cord
injury
(SCI)
represents
a
significant
medical
challenge,
often
resulting
in
permanent
disability
and
severely
impacting
the
quality
of
life
for
affected
individuals.
Traditional
treatment
options
remain
limited,
underscoring
need
novel
therapeutic
approaches.
In
recent
years,
multipotent
mesenchymal
stem
cells
(MSCs)
have
emerged
as
promising
candidate
SCI
due
to
their
multifaceted
regenerative
capabilities.
This
comprehensive
review
synthesizes
current
understanding
molecular
mechanisms
underlying
MSC-mediated
tissue
repair
SCI.
Key
discussed
include
neuroprotection
through
secretion
growth
factors
cytokines,
promotion
neuronal
regeneration
via
MSC
differentiation
into
neural
cell
types,
angiogenesis
release
pro-angiogenic
factors,
immunomodulation
by
modulating
immune
activity,
axonal
driven
neurotrophic
glial
scar
reduction
modulation
extracellular
matrix
components.
Additionally,
examines
various
clinical
applications
MSCs
treatment,
such
direct
transplantation
injured
spinal
cord,
engineering
using
biomaterial
scaffolds
that
support
survival
integration,
innovative
cell-based
therapies
like
MSC-derived
exosomes,
which
possess
neuroprotective
properties.
As
field
progresses,
it
is
crucial
address
challenges
associated
with
MSC-based
therapies,
including
determining
optimal
sources,
intervention
timing,
delivery
methods,
well
developing
standardized
protocols
isolation,
expansion,
characterization.
Overcoming
these
will
facilitate
translation
preclinical
findings
practice,
providing
new
hope
improved
individuals
living
devastating
consequences
Journal of Inflammation Research,
Год журнала:
2024,
Номер
Volume 17, С. 3307 - 3334
Опубликована: Май 1, 2024
Abstract:
Inflammatory
bowel
disease
(IBD)
is
a
chronic
inflammatory
of
the
gastrointestinal
tract,
which
has
high
recurrence
rate
and
incurable
due
to
lack
effective
treatment.
Mesenchymal
stromal
cells
(MSCs)
are
class
pluripotent
stem
that
have
recently
received
lot
attention
their
strong
self-renewal
ability
immunomodulatory
effects,
large
number
experimental
clinical
models
confirmed
positive
therapeutic
effect
MSCs
on
IBD.
In
preclinical
studies,
MSC
treatment
for
IBD
relies
paracrine
cell-to-cell
contact,
its
mediated
mitochondrial
transfer
immune
regulation.
It
also
plays
role
in
restoring
intestinal
mucosal
barrier
through
homing
effect,
regulation
microbiome,
repair
epithelial
cells.
latest
trials,
safety
efficacy
been
by
transfusion
autologous
or
allogeneic
bone
marrow,
umbilical
cord,
adipose
MSCs,
as
well
derived
extracellular
vesicles.
However,
regarding
stable
use
several
concerns
emerge,
including
cell
sources,
management
(dose,
route
frequency
administration,
pretreatment
MSCs)
adverse
reactions.
This
article
comprehensively
summarizes
effects
mechanisms
advantages
over
conventional
drugs,
trial
progress
The
current
challenges
future
directions
discussed.
review
would
add
knowledge
into
understanding
applying
MSCs.
Keywords:
mesenchymal
cells,
immunomodulation,
disease,
ulcerative
colitis,
Crohn's
therapy
Journal of Nanobiotechnology,
Год журнала:
2024,
Номер
22(1)
Опубликована: Окт. 26, 2024
Radiation-induced
lung
injury
(RILI)
is
associated
with
alveolar
epithelial
cell
death
and
secondary
fibrosis
in
injured
lung.
Mesenchymal
stem
(MSC)-derived
exosomes
have
regenerative
effect
against
the
potential
to
intervene
of
RILI.
However,
their
intervention
efficacy
limited
because
they
lack
targeting
characters
do
not
carry
sufficient
specific
effectors.
SARS-CoV-2
spike
glycoprotein
(SARS-CoV-2-S-RBD)
binds
angiotensin-converting
enzyme
2
(ACE2)
receptor
mediates
interaction
host
cells.
MiR-486-5p
a
multifunctional
miRNA
angiogenic
antifibrotic
acts
as
an
effector
MSC-derived
exosomes.
Ferroptosis
form
radiation
injury,
its
roles
mechanisms
RILI
remain
unclear.
In
this
study,
we
developed
engineered
SARS-CoV-2-S-RBD-
miR-486-5p-
modification
investigated
effects
on
RIPF
action
via
suppression
ferroptosis.
Adenovirus-mediated
gene
led
miR-486-5p
overexpression
human
umbilical
cord
MSC
(p
<
0.05),
thereby
constructing
(miR-486-MSC-Exo).
MiR-486-MSC-Exo
promoted
proliferation
migration
irradiated
mouse
(MLE-12)
cells
vitro
inhibited
vivo
(all
p
0.05).
suppressed
ferroptosis
MLE-12
cells,
assay
revealed
that
expression
fibrosis-related
genes
up-regulated
following
(both
reversed
induced
by
TGF-β1
improved
pathological
mice
SARS-CoV-2-S-RBD-modified
miR-486-5p-engineered
(miR-486-RBD-MSC-Exo)
were
also
constructed,
distribution
DiR
dye-labeled
miR-486-RBD-MSC-Exo
hACE2CKI/CKI
Sftpc-Cre+
demonstrated
long-term
retention
MiR-486-RBD-MSC-Exo
significantly
survival
rate
changes
Furthermore,
miR-486-MSC-Exo
exerted
anti-fibrotic
targeted
SMAD2
inhibition
Akt
phosphorylation
activation
Engineered
miR-486-5p-modification
developed.
vitro,
alleviated
ACE2
humanized
vivo.
activation.
This
study
provides
approach
for
intervention.
Biomedicine & Pharmacotherapy,
Год журнала:
2023,
Номер
165, С. 115135 - 115135
Опубликована: Июль 13, 2023
Exosomes,
remarkable
extracellular
vesicles,
have
emerged
as
an
advanced
frontier
in
intercellular
communication.
This
capacity
positions
them
promising
contenders
drug
delivery
systems
(DDSs)
for
osteoarthritis
(OA)
therapy,
capitalizing
on
their
inherent
biocompatibility,
stability,
and
minimal
immunogenicity.
In
this
comprehensive
review,
we
summarize
the
emerging
developments
surrounding
exosome-based
DDSs
OA
therapy.
Focusing
exosome
origins,
meticulously
explore
diverse
sources
contributing
to
production,
including
invaluable
stem
cells,
immune
array
of
other
cell
types.
addition,
unravel
underlying
mechanisms
action
that
govern
these
exosome-borne
therapeutics,
illuminating
intricate
interplay
between
exosomes
recipient
cells.
summary,
review
highlights
present
challenges
permeate
Through
in-depth
exploration
intricacies
within
field,
aims
shed
light
future
direction
OA.
It
serves
a
bridge
fostering
collaboration
collective
efforts
reshaping
treatment
landscape
The
2019
novel
coronavirus
disease
(COVID-19)
pandemic
caused
by
severe
acute
respiratory
syndrome
2
(SARS-CoV-2)
is
ongoing,
and
has
necessitated
scientific
efforts
in
diagnosis,
treatment,
prevention.
Interestingly,
extracellular
vesicles
(EVs)
have
been
crucial
these
developments.
EVs
are
a
collection
of
various
nanovesicles
which
delimited
lipid
bilayer.
They
enriched
proteins,
nucleic
acids,
lipids,
metabolites,
naturally
released
from
different
cells.
Their
natural
material
transport
properties,
inherent
long-term
recycling
ability,
excellent
biocompatibility,
editable
targeting,
inheritance
parental
cell
properties
make
one
the
most
promising
next-generation
drug
delivery
nanocarriers
active
biologics.
During
COVID-19
pandemic,
many
made
to
exploit
payload
for
treatment
COVID-19.
Furthermore,
strategies
that
use
engineered
manufacture
vaccines
neutralization
traps
produced
efficacy
animal
experiments
clinical
trials.
Here,
recent
literature
on
application
damage
repair,
prevention
reviewed.
And
therapeutic
value,
strategies,
safety,
biotoxicity
production
applications
EV
agents
as
well
inspiration
using
block
eliminate
viruses
discussed.
